Clinical characteristics associated with the severity of Clostridium [Clostridioides] difficile infection in a tertiary teaching hospital from Mexico

Laura Tijerina-Rodríguez d, Elvira Garza-González b,*, Adrián Martínez-Meléndez d, Rayo Morfín-Otero a, Adrián Camacho-Ortiz c, Esteban González-Díaz a, Héctor Raúl Perez-Gómez a, Licet Villarreal-Treviño d, Héctor Maldonado-Garza b, Sergio Esparza-Ahumada a, Eduardo Rodríguez-Noriega a

a Hospital Civil de Guadalajara, Fray Antonio Alcalde, Instituto de Patología Infecciosa y Experimental, Centro Universitario de Ciencias de La Salud, Universidad de Guadalajara, Mexico
b Servicio de Gastroenterología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Mexico
c Servicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Mexico
d Laboratorio de Microbiología General, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, Mexico

A R T I C L E   I N F O
Article history:
Received 12 November 2018
Accepted 18 February 2021
Available online 23 February 2021

Keywords:
Severity
Clostridioides difficile
Recurrence
CDI

A B S T R A C T
Background: Clostridium difficile infection (CDI) is a leading cause of healthcare-associated diarrhea worldwide. In this study, risk factors associated with the development of severe-complicated and recurrent outcomes in CDI patients in different age groups, including the non-elderly, were assessed in a third-level hospital.

Methods: CDI cases were detected by clinical data and polymerase-chain-reaction (PCR). Clinical, demographic, epidemiological, and microbiological risk factors for CDI were evaluated.

Results: During the study period, 248 out of 805 patients with nosocomial diarrhea were diagnosed with CDI and the majority were severe-complicated cases (87.90%). Female gender (OR 3.19, 95% CI 1.19–8.55, p = 0.02) and lymphoma (OR 3.95, 95% CI 1.03–15.13, p = 0.04) were risk factors for severe-complicated CDI. Mature adulthood (51–60 years) (OR 5.80, 95% CI 1.56–21.62, p = 0.01), previous rifampicin use (OR 7.44, 95% CI 2.10–26.44, p = 0.00), and neoplasm (solid malignant neoplasm or hematological malignancies) (OR 4.12, 95% CI 1.01–16.83, p = 0.04) were risk factors for recurrent infection. Autoimmune disorders (OR 6.62, CI 95% 1.26–34.73, p = 0.02), leukemia (OR 4.97, 95% CI 1.05–23.58, p = 0.04), and leukemia

* Corresponding author. Gastroenterology Service, Dr. José Eleuterio González University Hospital, New Autonomous University, Avenida Madero s/n Colonia Mitras Centro, Monterrey, Nuevo Leon 64460, Mexico.
E-mail address: elvira_garza_gzz@yahoo.com (E. Garza-González).
Peer review under responsibility of Chang Gung University.

https://doi.org/10.1016/j.bj.2021.02.007
2319-4170/© 2021 Chang Gung University. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Clostridium difficile (recently reclassified as Clostridioides difficile) infection (CDI) is a leading cause of healthcare-associated diarrhea worldwide. Some known risk factors for acquiring CDI are advanced age (>65 years), the use of broad-spectrum antibiotics, extended hospital stays, stay in the intensive care unit, cancer, leukemia, lymphoma, gastrointestinal procedures, and the use of immunosuppressive drugs, antacids and steroids.

What this study adds to the field

In our study, young (21–30 years) and mature adults (51–60 years) had the highest frequency of CDI. Colistin use was identified as a new risk factor for increased 30-day mortality, and the use of rifampin treatment was a new risk factor for the development of recurrent episodes.

The present study aimed to identify risk factors associated with the development of severe-complicated, and recurrent outcomes in CDI patients of different age groups, including the non-elderly, in a third-level hospital.

Materials and methods

Study setting and population

This was a retrospective study at the Hospital Civil de Guadalajara Fray Antonio Alcalde, a 1000-bed tertiary-care teaching hospital. The hospital has 31 wards housed in four separate buildings. The hospital provides services to Guadalajara in the state of Jalisco, Mexico, with approximately 30,000 admissions each year.

Patient demographics and CDI diagnosis

As part of the surveillance protocol for CDI, between November 2013 and December 2015, all hospitalized patients with a hospital stay more significant than 48 h who developed diarrhea (3 or more depositions in the last 24 h with a Bristol score of 6 or 7 or a recent hospitalization in the previous 12 weeks) were tested for C. difficile using the Cepheid Xpert C. difficile/Epi test (Cepheid, Sunnyvale CA).

Epidemiological and clinical data were reviewed in medical records from CDI patients

CDI was defined as complicated when one of the following criteria were present: admission to the intensive care unit, hypotension with or without the required use of vasopressors, fever ≥38.5 °C, ileus, significant abdominal distention, mental status changes, white blood cell (WBC) count ≥35,000 cells/mm³ or <2000 cells/mm³ or serum lactate levels >2.2 mmol/l [10]. CDI was defined as severe because of hypoalbuminemia (serum albumin <3 g/dl), WBC ≥15,000 cells/mm³, or abdominal tenderness [10].

Cases not meeting the severe or complicated infection criteria were classified as having mild to moderate CDI (without additional symptoms)

Recurrent CDI was defined by the reoccurrence of diarrhea associated with clinical and laboratory evidence of CDI within eight weeks after completing therapy or resolution of the initial CDI, [10]. The study was reviewed and approved by the Ethics Committee of the “Hospital Civil de Guadalajara Fray Antonio Alcalde.”
Statistical analyses

The patients were classified into the following age group: 11–20, 21–30, 31–40, 41–50, 51–60, and >60 years of age. For the analyses of categorical variables, Pearson’s chi-squared and Fisher’s exact tests were used; for continuous variables, the Mann–Whitney U test was used. The Kruskal–Wallis test was performed for comparison between severe-complicated and recurrent CDI, as well as NAP1/027-associated CDI, 30-day, and 12-month mortality frequencies among age groups.

A multivariable logistic regression was conducted over two stages: a univariable analysis to identify significant associations between independent variables and outcomes. Odds ratios with a 95% confidence interval were determined. Variables identified in the univariate analysis with odds ratios >1.0 and \( p < 0.25 \) were included in a binary logistic regression model. Variables with a \( p < 0.05 \) were considered as independent risk factors.

We examined multi-collinearity using linear regression to study the tolerance index (Ti) and the variance inflation factor (VIF) for the absence of multicollinearity issues between independent variables by the Statistical Package for the Social Sciences (SPSS), software version 23.

Results

Epidemiological and clinical data

During the study period, 805 patients presented with nosocomial diarrhea, and 248 were confirmed to have CDI by PCR (62.10% were males, and 75% were <60 years old). Most patients with CDI were young adults (age, 21–30 years; \( n = 46, 18.85% \)) or mature adults (51–60 years of age; \( n = 45, 18.44% \)) [Table 1].

Most patients presented with severe-complicated disease (87.70%). Hypoalbuminemia \( n = 148, 60.65% \), abdominal pain \( n = 115, 47.13\% \), fever >38.5 °C \( n = 103, 42.21\% \), abdominal distension \( n = 102, 41.80\% \), and mucus in stool \( n = 102, 41.80\% \) were the most common signs and symptoms associated with CDI. The most frequently observed comorbidities included arterial hypertension (38.11%), kidney disease (34.40%), diabetes mellitus (31.55%), and neoplasm (25.82%).

Table 1 Demographic and epidemiological characteristics of patients with confirmed CDI (\( N = 244^{a} \)).

| Category | \( N \) | \% |
|----------|--------|----|
| Gender   |        |    |
| Male     | 154    | 63.10 |
| Female   | 90     | 36.90 |
| Age groups (years) |        |    |
| 11–20    | 29     | 11.88 |
| 21–30    | 46     | 18.85 |
| 31–40    | 25     | 10.25 |
| 41–50    | 37     | 15.16 |
| 51–60    | 45     | 18.44 |
| 61–70    | 32     | 13.11 |
| >70      | 21     | 8.60  |
| >80      | 9      | 3.69  |
| Severity of infection |        |    |
| Severe-complicated | 214 | 87.70 |
| Moderate  | 30     | 12.29 |
| Clinical data |        |    |
| Abdominal pain | 115  | 47.13 |
| Fever (>38 °C) | 103  | 42.21 |
| Abdominal distention | 102  | 41.80 |
| Mucus in stool | 102  | 41.80 |
| Vomiting | 37     | 15.16 |
| Blood in stool | 17   | 6.97  |
| Pseudomembranes | 9    | 3.69  |
| Laboratory results |        |    |
| Hypoalbuminemia | 148  | 60.65 |
| White blood cells (>15,000 cells/mm\(^3\)) | 76  | 31.14 |
| Comorbidities |        |    |
| Arterial hypertension | 93   | 38.11 |
| Kidney disease | 84    | 34.40 |
| Diabetes mellitus | 77    | 31.55 |
| Neoplasm (solid malignant neoplasm or hematological malignancies) | 63 | 25.82 |
| Pneumonia | 37     | 15.16 |
| Lymphoma | 11     | 4.51  |
| Leukemia | 8      | 3.28  |
| Autoimmune disorder | 6  | 2.46  |
| Other | 19     | 7.79  |
| C. difficile strain characteristics |        |    |
| NAP1/027 strain | 127  | 52.05 |
| non-NAP1/027 | 117   | 47.95 |
| Recurrence |        |    |
| At least one | 22/84 | 26.19 |
| Due to C. difficile NAP1/027 strain | 10/22 | 45.45 |
| Due to non-C. difficile NAP1/027 strain | 12/22 | 54.55 |
| Hospitalization |        |    |
| General ward (before and after diagnosis) | 222 | 90.98 |
| In the previous 12 weeks | 124  | 50.82 |
| Intensive Care Unit | 20 | 9.01 |
| Antibiotic treatment before CDI diagnosis |        |    |
| Overall | 165    | 67.62 |
| Clindamycin | 128  | 77.58 |
| Cephalosporins | 89  | 53.94 |
| Carbenapens | 54   | 32.73 |
| Metronidazole | 35   | 21.21 |
| Fluoroquinolones | 23  | 13.94 |
| Linezolid | 21    | 12.73 |
| Vancomycin | 19   | 11.52 |
| Rifampin | 19    | 11.52 |
| Amikacin | 15    | 9.09  |
| Piperacillin-tazobactam | 15  | 9.09  |
| Fluconazole | 12   | 7.27  |
| Others | 27     | 16.36 |

Table 1 — (continued) \(^{a}\)

| Category | \( N \) | \% |
|----------|--------|----|
| Another drug treatment |        |    |
| Histamine blockers | 14  | 5.73 |
| Proton pump inhibitors (PPI) | 204  | 83.61 |
| Immunosuppressors | 36  | 14.75 |
| CDI cases per year\(^{b}\) |        |    |
| 2014 | 68  | 27.42 |
| 2015 | 177 | 71.37 |
| 30-day mortality |        |    |
| Overall | 38  | 15.57 |
| 12-month mortality |        |    |
| Overall | 69  | 28.27 |

\(^{a}\) Clinical data were available for 244 patients only.

\(^{b}\) 2013 frequency was not included since only 2-month period data was available for this year.
were arterial hypertension (n = 93, 38.11%), kidney disease, including patients that presented urinary infection or creatinine levels >1.5 mg/dl (n = 84, 34.40%), and diabetes (n = 77, 31.55%) [Table 1].

The hypervirulent C. difficile NAP1/027 strain was detected in 127 (52.04%) patients, and 84 of these patients were followed for the next eight weeks; among them, 22 patients (26.19%) developed at least one recurrent episode. From the recurrent episodes, 10/22 (45.40%) were caused by the C. difficile NAP1/027 strain and 12/22 (54.50%) by a non-NAP1/027 strain.

Most patients (n = 222) were housed in the general ward, and among them, 124 had been hospitalized during the 12 weeks previous to CDI. Twenty patients had been admitted to the intensive care unit when CDI was diagnosed. The remaining two patients were in other wards. All patients with the first episode of mild to moderate CDI were treated with metronidazole, and recurrent episodes were treated with metronidazole in combination with vancomycin according to the American College of Gastroenterology guidelines and the Guidelines for C. difficile Infection in Adults and Children of the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Second-line therapies, such as fidaxomicin treatment or a fecal microbiota transplant, were not used due to their unavailability at that time in our hospital.

Almost two-thirds of the patients had previously received antibiotic treatment (n = 165, 67.62%), most commonly clindamycin (n = 128, 77.58%) and cephalosporins (n = 89, 53.94%); metronidazole and vancomycin were previously administered in 21.21% and 11.52% of the cases, respectively which are usually administered for CDI treatment [Table 1]. From the CDI 248 cases, 3 (1.21%) occurred in 2013, 68 (27.42%) in 2014, and 177 (71.37%) in 2015.

### Risk factors detected for CDI

Female gender (OR 3.19, 95% CI 1.19 – 8.55, p = 0.02) and lymphoma (OR 3.95, 95% CI 1.03 – 15.13, p = 0.04) were independent risk factors for severe CDI [Table 2].

Mature adulthood (51–60 years) (OR 5.80, 95% CI 1.56 – 21.62, p = 0.01), rifampin consumption (OR 7.44, 95% CI 2.10 – 26.44, p = 0.00) and neoplasm (solid malignant neoplasm or hematological malignancies) (OR 4.12, 95% CI 1.01 – 16.83, p = 0.04) were independent risk factors for the development of recurrent CDI [Table 2].

We identified the following independent risk factors for 30-day mortality rates: autoimmune disorders (OR 6.62, 95% CI 1.26 – 34.73, p = 0.02), leukemia (OR 4.97, 95% CI 1.05 – 23.58, p = 0.04), lymphoma (OR 4.97, 95% CI 1.05 – 23.58, p = 0.04) and previous colistin treatment (OR 4.97, 95% CI 1.05 – 23.58, p = 0.04) [Table 2].

### Discussion

Our study addressed risk factors among patients with CDI, and we detected that 89.0% of the patients developed severe CDI. In contrast to previous reports that identified the elderly (>60 years) to be the most vulnerable age group [3,11–16], in our study, young (age 21–30 years) and mature adulthood (age 51–60 years) adults had the highest frequency of CDI, respectively 18.55% and 18.15%. Previous studies conducted in Mexico reported that patients <65 years of age had a higher risk of recurrent CDI [17–19]. This Mexican study identified mature adulthood (51–60 years) as an independent risk factor for the development of recurrent CDI. The different conclusions with respect to the most vulnerable age group may be explained by the fact that most CDI surveillance studies have focused primarily on the elderly, excluding younger adults and children [3,20,21]. Furthermore, the healthcare facility where the study was conducted also provided medical attention mainly to traumatized younger patients and was better equipped to identify this novel, at-risk population.

The prevalence of the NAP1/027 C. difficile strain in about half of our CDI patients is consistent with reports from other countries where prevalence was between 45 and 61% [19].

The present study confirmed previously described risk factors for complicated or recurrent CDI [3,12,22,23], e.g.,

### Table 2 Risk factors for the development of severity, recurrence, and 30-day mortality.

| Dependent Variable | Univariate analysis | Binary logistic regression |
|--------------------|---------------------|---------------------------|
| Severe CDI<sup>a</sup> | Gender (females) | U-OR<sup>a</sup> (95% CI) | p-value | A-OR<sup>a</sup> (95% CI) | p-value |
|                    | 2.58 (1.00 – 6.51) | 0.03<sup>*</sup> | 3.19 (1.19 – 8.55) | 0.02<sup>*</sup> |
|                    | Lymphoma            | 1.33 (0.89 – 1.99) | 0.04<sup>*</sup> | 3.95 (1.03 – 15.13) | 0.04<sup>*</sup> |
|                    | Age (21–30 years)   | 1.51 (0.98 – 1.35) | 0.03<sup>*</sup> | 2.41 (1.00 – 3.78) | 0.05 |
|                    | Infection with 027 strain | 1.67 (0.77 – 3.64) | 0.13 | 0.56 (0.25 – 1.26) | 0.16 |
| Recurrence<sup>b</sup> | Age (51–60 years) | 6.54 (2.07 – 20.68) | 0.00<sup>**</sup> | 5.80 (1.56 – 21.62) | 0.01<sup>*</sup> |
|                    | Antibiotics intake | 2.19 (0.57 – 8.44) | 0.19 | 1.42 (0.31 – 6.43) | 0.64 |
|                    | Rifampin            | 4.37 (0.89 – 21.37) | 0.07 | 7.44 (2.10 – 26.44) | 0.00<sup>**</sup> |
|                    | Neoplasms           | 2.42 (0.79 – 7.47) | 0.10 | 4.12 (1.01 – 16.83) | 0.04<sup>*</sup> |
|                    | Fluoroquinolones    | 2.74 (0.74 – 10.12) | 0.11 | 2.55 (0.55 – 11.73) | 0.23 |
|                    | Hypertension        | 1.23 (0.46 – 3.29) | 0.67 | 1.62 (0.48 – 5.49) | 0.23 |
| 30-day-mortality<sup>c</sup> | Autoimmune disorder | 5.09 (0.97 – 26.24) | 0.03<sup>*</sup> | 6.62 (1.26 – 34.73) | 0.02<sup>*</sup> |
|                    | Leukemia            | 3.90 (0.84 – 18.24) | 0.09 | 4.97 (1.05 – 23.58) | 0.04<sup>*</sup> |
|                    | Lymphoma            | 2.62 (0.75 – 9.21) | 0.12 | 3.79 (1.03 – 12.07) | 0.04<sup>*</sup> |
|                    | Colistin            | 3.79 (0.81 – 17.70) | 0.10 | 4.97 (1.05 – 23.58) | 0.04<sup>*</sup> |

Goodness of fit test: Hosmer y Lemeshow, *x<sup>2</sup> = 3.878, p = 0.567, *<sup>b</sup>x<sup>2</sup> = 4.657, p = 0.702, *<sup>c</sup>x<sup>2</sup> = 0.167, p = 0.683. *p < 0.05, **p < 0.01. *<sup>d</sup>Unadjusted odds-ratio, *<sup>e</sup>Adjusted odds-ratio.
middle-aged adulthood and neoplasm illness were independent risk factors for recurrent CDI, whereas lymphoma was an independent risk factor for complicated CDI.

As far as we know, we are the first to report that rifampin and colistin are independent risk factors for recurrent CDI and 30-day mortality, respectively. It should be noted, though, that only seven patients received colistin therapy before the CDI diagnosis. This risk factor is significant because recent studies have reported infections due to multidrug-resistant strains that were only susceptible to colistin. This antibiotic was not used until recently because of its nephrotoxicity. However, during the last decade, it has been reintroduced to treat critical illnesses such as pneumonia, bacteremia, meningitis, obstructive pulmonary disease, and cystic fibrosis [24–26]. However, in the treatment of pneumonia, bacteremia, and other critical diseases related to the development of CDI, a high mortality rate (61.9%) has been attributed to colistin therapy (OR, 1.99 to 8.2; p < 0.001) [24,25].

It should be mentioned that our hospital had an outbreak of carbapenem-resistant enterobacteria during the study period; thus, the use of tigecycline and colistin was increased. Regarding colistin as an independent risk factor for mortality, we must consider that these patients had severe clinical conditions, and the high mortality rate may be due to the underlying infection. In this regard, a prediction model using logistic regression for CDI in hospitalized patients identified an underlying infection as an independent predictor of CDI [27].

Still, this newly described risk factor for the development of CDI reinforced the need for control of other hospital-acquired infectious diseases as an additional means of preventing CDI. As a result, in our hospital, quinolone was reduced, and the use of levofloxacin was eliminated from almost all wards except for the hematology and urology wards.

We used the Xpert C. difficile/Epi assay to confirm CDI. This assay detects the genes tcdB and cdt and the 18-bp deletion in tcdC, but it does not identify the tcdA gene. Therefore, it is possible that patients infected with strains that only produced tcdA were not identified. On the other hand, it seems that the production of only toxin A is rare. A study that compared CDI detection by either the Xpert C. difficile with detection by the tcdA-based illumigene C. difficile assay (Meridian Bioscience, Inc.) found that 157 samples were negative in both tests, 35 were positive in both assays, 7 were positive by GeneXpert but negative by the illumigene assay, and in one case, the GeneXpert was positive. However, the result of illumigene was invalid [28]. Thus, the lack of detection of tcdA by the GeneXpert may have had a minimal effect in our study.

The major limitation of our study was that it was performed at a single site, and results may not apply to other hospitals. The high number of complicated CDI infections in our hospital and their associated risk factors may be advocated by increased infections caused by carbapenem-resistant enterobacteria during the study period.

**Conclusion**

In summary, in our study, CDI was mainly prevalent among patients <60 years, who were also more vulnerable to severe CDI. The use of colistin was identified as a new risk factor for increased 30-day mortality rates, while the use of rifampin treatment was a new risk factor for the development of recurrent episodes in patients between the ages of 51 and 60 years.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Conflicts of interest**

The authors report no conflicts of interest.

**Ethics in publishing**

This study was reviewed and approved by the Ethics Comitee of “Hospital Civil de Guadalajara, Fray Antonio Alcalde”.

**REFERENCES**

[1] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–34.

[2] Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol 2015;63:193–202.

[3] Cohen SH, Gerring MA, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Society for Healthcare Epidemiology of A, Infectious Diseases Society of A. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–55.

[4] Balassiano IT, Yates EA, Domingues RM, Ferreira EO. Clostridium difficile: a problem of concern in developed countries and still a mystery in Latin America. J Med Microbiol 2012;61:169–79.

[5] Marcon AP, Gamba MA, Vianna LA. Nosocomial diarrhea in the intensive care unit. Braz J Infect Dis 2006;10:384–9.

[6] Legaria MC, Lumelsky G, Rosetti S. Clostridium difficile-associated diarrhea from a general hospital in Argentina. Anaerobe 2003;9:113–6.

[7] Fernandez Canigia L, Nazar J, Arce M, Dadamio J, Smayevsky J, Bianchini H. Clostridium difficile diarrhea: frequency of detection in a medical center in Buenos Aires, Argentina. Rev Argent Microbiol 2001;33:101–7.

[8] Herrera P, Cotera A, Fica A, Galdo T, Alvo M. High incidence and complications of Clostridium difficile diarrhea among patients with renal diseases. Rev Med Chil 2003;131:397–403.

[9] Garcia C, Velarde J, Cedron H, Ferrufino JC, Seas C, Bussalleu A, et al. Clostridium difficile and cytomegalovirus involved in a case of pseudomembranous colitis. Rev Gastroenterol Peru 2007;27:408–10.

[10] Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478–98.
[11] Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin N Am 2001;30:753–77.
[12] Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–60.
[13] Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009;144:433–9.
[14] Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772–8. Erratum in: Arch Intern Med 2010;170:1100.
[15] Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011;79:359–63.
[16] Reacher M, Verlander NQ, Roddick I, Trundle C, Brown N, Farrington M, et al. Excess mortality attributable to Clostridium difficile and risk factors for infection in an historic cohort of hospitalised patients followed up in the United Kingdom death register. PloS One 2016;11:e0149983.
[17] Camacho-Ortiz A, Lopez-Barrera D, Hernandez-Garcia R, Galvan-De Los Santos AM, Flores-Trevino SM, Llaca-Diaz JM, et al. First report of Clostridium difficile NAP1/027 in a Mexican hospital. PloS One 2015;10:e0122627.
[18] Van Werkhoven CH, van der Tempel J, Jajou R, Thijsen SF, Diepersloot RJ, Bonten MJ, et al. Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients treated with antibiotics. Clin Microbiol Infect 2015;21:786. e1-8.
[19] Pancholi P, Kelly C, Raczkowski M, Balada-Llasat JM. Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. J Clin Microbiol 2012;50:1331–5.